DE60130797D1 - Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose - Google Patents
Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenoseInfo
- Publication number
- DE60130797D1 DE60130797D1 DE60130797T DE60130797T DE60130797D1 DE 60130797 D1 DE60130797 D1 DE 60130797D1 DE 60130797 T DE60130797 T DE 60130797T DE 60130797 T DE60130797 T DE 60130797T DE 60130797 D1 DE60130797 D1 DE 60130797D1
- Authority
- DE
- Germany
- Prior art keywords
- stenosis
- antagonists
- treatment
- migration
- smooth muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US940101 | 1992-09-03 | ||
US22967900P | 2000-09-01 | 2000-09-01 | |
US229679P | 2000-09-01 | ||
US26551601P | 2001-01-31 | 2001-01-31 | |
US265516P | 2001-01-31 | ||
US09/940,101 US20020119148A1 (en) | 2000-09-01 | 2001-08-27 | ErbB4 antagonists |
PCT/US2001/026984 WO2002018444A2 (en) | 2000-09-01 | 2001-08-29 | Erbb4 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60130797D1 true DE60130797D1 (de) | 2007-11-15 |
DE60130797T2 DE60130797T2 (de) | 2008-08-07 |
Family
ID=27397993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60130797T Expired - Lifetime DE60130797T2 (de) | 2000-09-01 | 2001-08-29 | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose |
Country Status (12)
Country | Link |
---|---|
US (6) | US20020119148A1 (de) |
EP (1) | EP1351744B1 (de) |
JP (1) | JP2004507559A (de) |
AT (1) | ATE374642T1 (de) |
AU (2) | AU8691801A (de) |
CA (1) | CA2420062C (de) |
DE (1) | DE60130797T2 (de) |
DK (1) | DK1351744T3 (de) |
ES (1) | ES2295202T3 (de) |
HK (1) | HK1059404A1 (de) |
IL (2) | IL154495A0 (de) |
WO (1) | WO2002018444A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US20040156835A1 (en) * | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
WO2003101401A2 (en) * | 2002-06-03 | 2003-12-11 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
PT1585966E (pt) | 2002-07-15 | 2012-02-20 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4 |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
JP4527388B2 (ja) * | 2003-12-11 | 2010-08-18 | 東洋鋼鈑株式会社 | ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法 |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
EP1791565B1 (de) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Zystein-modifizierte Antikörper und Konjugate |
JP2008535795A (ja) * | 2005-03-07 | 2008-09-04 | ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー | チロシンキナーゼインヒビター組成物、並びに疾患の治療におけるそれらの製造及び使用のための方法 |
PL2716301T3 (pl) * | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
JP2011516423A (ja) | 2008-03-28 | 2011-05-26 | シー レーン バイオテクノロジーズ, エルエルシー | ウイルス抗原に対する中和分子 |
EA022884B1 (ru) * | 2008-08-15 | 2016-03-31 | Мерримак Фармасьютикалз, Инк. | СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА |
US20110293614A1 (en) | 2008-11-25 | 2011-12-01 | Klaus Elenius | Isoform specific anti-her4 antibodies |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
EP2507381A4 (de) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP3095871B1 (de) | 2010-02-08 | 2019-04-10 | Regeneron Pharmaceuticals, Inc. | Maus mit gemeinen leichten ketten |
WO2011107100A1 (en) | 2010-03-03 | 2011-09-09 | Aarhus Universitet | Methods and compositions for regulation of herv4 |
DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
CN103857700A (zh) | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | 串联fc双特异性抗体 |
CA2884431A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
PE20150955A1 (es) * | 2012-11-08 | 2015-06-20 | Hoffmann La Roche | Proteinas ligantes de antigeno anti-her3/her4 de union a la horquilla beta de her3 y a la horquilla beta de her4 |
US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
FR3020063A1 (fr) * | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
EP3143048B1 (de) | 2014-05-14 | 2019-08-28 | F. Hoffmann-La Roche AG | An die beta-haarnadel von her3 bindende anti-her3-antikörper |
CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0444961A1 (de) | 1990-03-02 | 1991-09-04 | Bristol-Myers Squibb Company | Her3: Ein neues EGF-Rezeptor Homologes |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
ES2206447T3 (es) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
GEP20012444B (en) * | 1994-11-14 | 2001-05-25 | Warner Lambert Company Us | 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation |
US5770567A (en) * | 1994-11-14 | 1998-06-23 | Genentech, Inc. | Sensory and motor neuron derived factor (SMDF) |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
CA2258721C (en) * | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
ATE290595T1 (de) * | 1996-07-12 | 2005-03-15 | Genentech Inc | Gamma-heregulin |
EP1864999B1 (de) * | 1996-11-27 | 2009-03-18 | Genentech, Inc. | Affinitätsreinigung von Polypeptid-Proteinen auf einer Matrix |
US6121415A (en) | 1997-07-09 | 2000-09-19 | Genentech, Inc. | ErbB4 receptor-specific neuregolin related ligands and uses therefor |
US6994856B1 (en) * | 1997-07-24 | 2006-02-07 | Genentech, Inc. | ErbB4 receptor-specific neuregulin related ligands and uses therefor |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
WO2001094413A2 (en) * | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
-
2001
- 2001-08-27 US US09/940,101 patent/US20020119148A1/en not_active Abandoned
- 2001-08-29 CA CA2420062A patent/CA2420062C/en not_active Expired - Fee Related
- 2001-08-29 AT AT01966399T patent/ATE374642T1/de active
- 2001-08-29 US US10/362,380 patent/US7332579B2/en not_active Expired - Fee Related
- 2001-08-29 EP EP01966399A patent/EP1351744B1/de not_active Expired - Lifetime
- 2001-08-29 ES ES01966399T patent/ES2295202T3/es not_active Expired - Lifetime
- 2001-08-29 WO PCT/US2001/026984 patent/WO2002018444A2/en active IP Right Grant
- 2001-08-29 AU AU8691801A patent/AU8691801A/xx active Pending
- 2001-08-29 JP JP2002523958A patent/JP2004507559A/ja active Pending
- 2001-08-29 DE DE60130797T patent/DE60130797T2/de not_active Expired - Lifetime
- 2001-08-29 AU AU2001286918A patent/AU2001286918B2/en not_active Ceased
- 2001-08-29 IL IL15449501A patent/IL154495A0/xx unknown
- 2001-08-29 DK DK01966399T patent/DK1351744T3/da active
-
2003
- 2003-02-17 IL IL154495A patent/IL154495A/en not_active IP Right Cessation
-
2004
- 2004-03-27 HK HK04102271A patent/HK1059404A1/xx not_active IP Right Cessation
-
2005
- 2005-10-11 US US11/248,122 patent/US20060093603A1/en not_active Abandoned
-
2006
- 2006-10-13 US US11/581,221 patent/US20070092513A1/en not_active Abandoned
-
2008
- 2008-06-24 US US12/215,200 patent/US7704498B2/en not_active Expired - Fee Related
-
2010
- 2010-04-02 US US12/753,792 patent/US20100190964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2420062A1 (en) | 2002-03-07 |
US7704498B2 (en) | 2010-04-27 |
ATE374642T1 (de) | 2007-10-15 |
CA2420062C (en) | 2014-04-01 |
US20060093603A1 (en) | 2006-05-04 |
AU2001286918B2 (en) | 2006-12-21 |
DE60130797T2 (de) | 2008-08-07 |
US20100190964A1 (en) | 2010-07-29 |
DK1351744T3 (da) | 2008-02-11 |
US20040052786A1 (en) | 2004-03-18 |
EP1351744B1 (de) | 2007-10-03 |
WO2002018444A3 (en) | 2003-07-31 |
AU8691801A (en) | 2002-03-13 |
US20020119148A1 (en) | 2002-08-29 |
IL154495A0 (en) | 2003-09-17 |
US7332579B2 (en) | 2008-02-19 |
JP2004507559A (ja) | 2004-03-11 |
US20070092513A1 (en) | 2007-04-26 |
IL154495A (en) | 2009-12-24 |
ES2295202T3 (es) | 2008-04-16 |
EP1351744A2 (de) | 2003-10-15 |
HK1059404A1 (en) | 2004-07-02 |
US20090068205A1 (en) | 2009-03-12 |
WO2002018444A2 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE376446T1 (de) | Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
CY1107453T1 (el) | Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις | |
MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
ATE494388T1 (de) | Neues verfahren zum erschaffen von proteinkinase- inhibitoren | |
ATE552849T1 (de) | Behandlungsverfahren unter verwendung von ctla-4 antikörpern | |
DE69527847T2 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
DE69519937T2 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
ATE267013T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
DE60236921D1 (de) | Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
MY141670A (en) | Material and method for treatment of timber | |
ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
DE602004004883D1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE69827387D1 (de) | Verwendung von pramipexol zur behandlung von restless-legs-syndrom | |
DE60239450D1 (de) | Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten | |
ATE239497T1 (de) | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |